Universitätsklinikum Jena | KIM II Häma/Onko - Studienzentrale KIM II

Research site

(Unclaimed)

Location

Am Klinikum 1, Jena, Thuringia, Germany

Site insights

Top conditions

Top treatments

Empagliflozin

Guselkumab

Atezolizumab

Ruxolitinib

Pembrolizumab

Golimumab

Dexamethasone

Bevacizumab

BI 1291583

Imatinib

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

45 of 186 total trials

A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden (Alternative-C)

The Alternative-C Trial is a prospective, multicenter Phase 2 Study to evaluate the efficacy of the chemotherapy-free combination of copanlisib and o...

Active, not recruiting

Follicular Lymphoma

Drug: Obinutuzumab

Drug: Copanlisib

A PRospective, rAndomizEd Comparison of subcuTaneOous and tRansvenous ImplANtable Cardioverter Defibrillator Therapy (PRAETORIAN)

This randomized controlled trial will outline the advantages and disadvantages of the subcutaneous implantable cardioverter defibrillator (ICD) compa...

Active, not recruiting

Ventricular Arrhythmias

Device: Implantation of transvenous ICD

Device: Implantation of subcutaneous ICD

A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms (VITALISScE™)

This study is open to adults aged 18 and older or above legal age who have systemic sclerosis. People can participate if they have a specific subtype...

Active, not recruiting

Scleroderma, Systemic

Drug: Placebo

Drug: Avenciguat (BI 685509)

Locations recently updated

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD)

The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.

Active, not recruiting

Crohn's Disease

Biological: JNJ-78934804

Biological: Golimumab

Locations recently updated

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC)

The purpose of this study is to evaluate the efficacy and safety of JNJ-78934804 as compared to guselkumab and golimumab in participants with moderat...

Active, not recruiting

Colitis, Ulcerative

Biological: JNJ-78934804

Drug: Placebo

A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)

This is a multi-center study to compare the efficacy and safety of itolizumab versus placebo as first-line therapy for subjects with Grade III-IV aGV...

Active, not recruiting

aGVHD

Graft Versus Host Disease

Drug: EQ001 Placebo

Biological: Itolizumab

A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with chronic rhinosinusitis and nasal pol...

Enrolling

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Drug: Standard therapy for INCS

Drug: LY3650150

A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM)

The purpose of this study is to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo in participants with symptomatic...

Active, not recruiting

Cardiomyopathy, Hypertrophic

Drug: Mavacamten

Other: Placebo

A Study of Ponsegromab in People With Heart Failure (GARDEN TIMI 74)

The primary purpose of this clinical trial is to compare the effects of study medicine (Ponsegromab/PF-06946860) with a placebo (an injection that lo...

Active, not recruiting

Heart Failure

Drug: Optional Cohort C: Ponsegromab low dose

Other: Optional Cohort C: Matched placebo

A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years

The purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placeb...

Enrolling

Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention

Biological: ExPEC9V

Other: Placebo

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell tr...

Enrolling

Multiple Myeloma

Drug: Lenalidomide

Drug: Iberdomide

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexameth...

Enrolling

Relapsed or Refractory Multiple Myeloma

Drug: Mezigdomide

Drug: Dexamethasone

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling

Atherosclerotic Cardiovascular Disease (ASCVD)

Elevated Lp(a)

Drug: Lepodisiran Sodium

Drug: Placebo

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

This prospective, randomized, multicenter, open-label Phase 2 study is designed to evaluate the superiority of InO monotherapy vs ALLR3 after 1 cycle...

Enrolling

ACUTE LYMPHOBLASTIC LEUKEMIA

Drug: ALLR3

Drug: Inotuzumab ozogamicin

A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone

This study is open to adults with head and neck cancer. The purpose of this study is to find out whether combining different study medicines makes tu...

Begins enrollment this month

Head and Neck Squamous Cell Carcinoma

Drug: Cetuximab

Drug: Pembrolizumab

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left...

Enrolling

Heart Failure

Drug: vicadrostat

Drug: Empagliflozin

Adjuvant Apalutamide in Subjects With High-risk Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy (ADAM)

The primary objective of this trial is to determine if adjuvant apalutamide in prostate cancer patients at high risk of developing subsequent metasta...

Active, not recruiting

Prostatic Neoplasms

Other: Standard of care

Drug: Apalutamide 60Mg Tab

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

This is a prospective, randomized, open-label, multicenter phase II study investigating the advancing Brigatinib properties in anaplastic lymphoma ki...

Active, not recruiting

NSCLC

Drug: Brigatinib

Drug: Tyrosine kinase inhibitor

Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

This is a phase III, randomized, partially blinded, multicenter trial to evaluate the efficacy and safety of atezolizumab plus bevacizumab and chemot...

Active, not recruiting

Recurrent Ovarian Carcinoma

Drug: Chemotherapy

Drug: Bevacizumab

Bemarituzumab in FGFR2b+ Patients with Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed At Least One Prior Line of Palliative Chemotherapy

The goal of this clinical trial is to evaluate if bemarituzumab in combination with different standard of care chemotherapies enhance tumor response...

Enrolling

Metastatic Gastro-esophageal Adenocarcinoma

Drug: bemarituzumab, trifluridine/tipiracil

Drug: bemarituzumab, irinotecan